Renaissance Pharma Report issue

For profit Phase 2 Phase 3
Founded: Newtown PA United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2014
NCT02094716
First Marketed Drug
2010
erythromycin (ilosone)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

acarrier@renaissancepharmainc.com | RENAISSANCE PHARMA | RENAISSANCE SSA LLC

Active Ingredients

Marketed Drugs (7)

erythromycin (ilosone) (1997)

fluconazole (diflucan) (2010)

milrinone (primacor) (2005)

naloxone (narcan) (2018)

nitroprusside (nipride) (2018)

oxacillin (pathocil) (2017)

pentobarbital (nembutal) (2017)

Drugs in Phase 3 Trials (3)

Key: Renaissance Pharma (0) Acquired (3)

azelaic acid (azelex) (1 trial)

econazole (spectazole) (1 trial)

pimecrolimus (elidel) (1 trial)

Drugs in Phase 2 Trials (2)

morphine (1 trial)

permethrin (nix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Scabies (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5